Stay updated with breaking news from Landmark Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
News Release Media Contacts: Jessica Castles Smith +1 732-501-8181 Satu Glawe +49 172-294-6264 ... | June 5, 2023
BioNTech SE Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dos...